Register now to R3i !
Your Login
Your Password
Confirm Password  
Your Email

RESIDUAL RISK THROUGH LANDMARK STUDIES

During the last 15 years, large prospective clinical trials have proven that :
  • statin therapy may reduce the risk of major cardiovascular events by 25 to 35%. However, despite effective low-density lipoprotein cholesterol (LDL-C) lowering treatment, significant cardiovascular (CV) risk persists.
  • even aggressive multifactorial therapy (statins, blood pressure lowering agents, anti-diabetic agents) did not prevent the development or progression of microvascular complications in patients with type 2 diabetes.
This section propose to put the results of these large clinical trials into perspective both on macro- and microvascular residual risk.
Macrovascular Residual Risk Studies
Microvascular Residual Risk Studies
Micro- and Macrovascular Residual Risk Studies